Company intelligence / Profile preview

Jing Medicine Technology

Shanghai, Shanghai Shi, China

Ownership: Private
Development stage: Other

Overview

Lead candidate HJ-002-03, an EGFR C797S inhibitor, is in Phase 1 for EGFR-mutated non-small cell lung cancer. Multiple small molecule and monoclonal antibody programs are in preclinical development, leveraging a proprietary proteolysis-targeting platform. Recent US FDA and China NMPA IND approvals for EED inhibitor HJM-353 highlight pipeline progress[5][9].

Therapeutic areas: ImmunologyEndocrinologyInfectious DiseasesHematologyOncologyNeurology
Modalities: Small moleculeMonoclonal antibodyProteolysis-targeting chimeras (PROTAC)
Industry: Biotech

Drug pipeline

1 asset

HJ-004-02

Partnerships

ShanghaiTech University ($100M strategic drug discovery collaboration; co-development, IP transfer, royalties)[1][4]

Beyond the preview

Go deeper on Jing Medicine Technology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Jing Medicine Technology.

Explore the full profile